Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|August 18, 2011
StudyManager Evolve Gaining Momentum in Chinese Market
Advertisement
Both deployments represent significant milestones for StudyManager, which began its expansion into China in early 2009. Demand for StudyManager Evolve, the company’s sponsor/CRO-focused product, has gained traction internationally following the success of numerous clinical trials and increased market share in the United States.
“We spent more than a year evaluating EDC systems that include both US. and Chinese vendors’ products,” said Dr. Ivan Zhai, CEO of GCP ClinPlus Ltd. “We selected Evolve as our EDC system because it is a simple, easy-to-use system that our sites are excited to use, with minimal user training. This should improve data entry compliance and data quality right from the start, while maintaining happy site users.”
Chongqing Jiachen Biotechnology Ltd. found Evolve to be flexible and easy to use—an ideal solution for managing data on behalf of the small- to mid-size biotechnology and pharmaceutical companies for which Chongqing Jiachen manages clinical trials.
Evolve's web-based interface integrates clinical trial management and electronic data capture tools. These features are highly scalable, and can be used together seamlessly or independently. Evolve enables users to create a single, centralized and secure location for key study information, simplifying study operations and enhancing team efficiency.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
4
Where AI Governance in Clinical Development Falls Short
5